JC-1: A very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia

Blood

Volumn 97, Issue 2, 2001, Pages 502-508

  Legrand, Ollivier ^a   Perrot, Jean Yves ^b   Simonin, Ghislaine ^b   Baudard, Marion ^b   Marie, Jean Pierre ^b  

^a HÔTEL DIEU   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DAUNORUBICIN; FLUORESCENT DYE; GLYCOPROTEIN P; RHODAMINE 123;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DISEASE ACTIVITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REMISSION; TREATMENT OUTCOME; TUMOR RESISTANCE;

EID: 0035863748     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.2.502     Document Type: Article

References (46)

1. Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16 years period
2. MDR1/P-glycoprotein in haematological neoplasms
3. Quality control of multidrug resistance assays in adult acute leukemia: Correlation between assays for P-glycoprotein expression and activity
4. Methods to detect P-glycoprotein-associated multidrug resistance in patient tumors: Consensus recommendations
5. Multicentric evaluation of the MDR phenotype in leukemia
6. Measuring multidrug resistance expression in human malignancies: Elaboration of consensus recommendations
7. A new method for cytofiuorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5′,6,6′-tetrachloro-1,1′,3,3′-tettraethylbenzimidaz ol-carbocyanine iodine (JC-1)
8. Functional assay of multidrug resistant cells using JC-1, a carbocyanine fluorescent probe
9. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate forming lipophilic cation JC-1
10. The morphological classification of acute lymphoblastic leukaemia: Concordance among observers and clinical correlations
11. Proposed revised criteria for the classification of acute myeloid leukemia
12. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial
13. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients
14. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group study
15. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia
16. Chemosensitivity testing: Another chapter
17. In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukemia
18. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia
19. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia
20. Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay
21. Non-parametric estimation from incomplete observations
22. Regression models and life tables
23. Analysis of apoptosis by laser scanning cytometry
24. The novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus
25. Alterations in mitochondrial structure and function are early events of dexamethasone-induced thymocyte apoptosis
26. JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess delta psi changes in intact cells: Implications for studies on mitochondrial functionality during apoptosis
27. Pleitropic phenotype of colchicine-resistant CHO cells: Cross-resistance and collateral sensitivity
28. A surface glycoprotein modulating drug permeability in chinese hamster ovary cell mutants
29. Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?
30. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: A Southwest Oncology Group study
31. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics
32. The immunophenotype of 177 adult acute myeloid leukemias: Proposal of a prognostic score
33. Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay
34. Overexpression of lung resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival
35. Use of standardized flow cytometric determinants of multidrug resistance to analyse response to remission induction chemotherapy in patients with acute myeloblastic leukaemia
36. Use of fluorescent dyes as molecular probes for the study of multidrug resistance
37. Role of MRP1 in multidrug resistance in acute myeloid leukemia
38. Lung resistance protein (LRP) gene expression in adult acute myeloid leukemia: A critical evaluation by three techniques
39. Functional multidrug resistance pheno-type associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-d-arabinosylcytosine sensitivity may predict clinical response in acute myeloid leukemia
40. P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positives acute myeloid leukemia
41. Phase III study of PSC-833 modulation of multidrug resistance (MDR) in previously untreated acute myeloid leukemia (AML) patients (PTS) 60 years (CALGB 9720)
42. Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: Randomized phase III trial (E2995)
43. Apoptosis and the dilemma of cancer chemotherapy
44. The drug efflux protein, P-glycoprotein, additionally protects drug resistant tumor cells from multiple forms of caspase-dependent apoptosis
45. P-glycoprotein protects leukemia cells against caspase dependent, but not caspase independent, cell death
46. P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway